(Raleigh, N.C.) BioDelivery Sciences International, Inc. (Nasdaq:BDSI) announced today that its abstract showing the results of a Phase 2 clinical study of BEMA Buprenorphine in the treatment of pain has been selected for oral presentation at Pain Week 2010, a national conference educating frontline clinicians who are faced with treating patients with pain. The presentation will take place on Friday, September 10, as part of the 7:00 - 9:00 AM podium presentation session. (more…)

(Research Triangle Park, N.C.) Tranzyme Pharma announced today that John Wo, MD, Professor of Medicine, Director, Clinical Research, Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, KY, will present ulimorelin Phase 2 data at this year’s Joint International NGM Meeting on Saturday, August 28, 2010. The conference is being held at the Westin Copley Place in Boston, MA. Professor Wo is scheduled to speak at 11:00am during Oral Session 3. (more…)

  (Durham, N.C.) Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today it has entered into an Executive Employment Agreement with Charles A. Johnson, M.D., who will become Executive Vice President of Research and Development and Chief Medical Officer, effective September 15, 2010. (more…)

(Washington, D.C.) Pharmaceutical research and biotechnology companies in New Jersey, California, New York and North Carolina are responsible for 192 of the 313 medicines in development today to treat mental illnesses, a new survey shows. The study “Medicines in Development for Mental Illnesses” compiled by the Pharmaceutical Research and Manufacturers of America (PhRMA) shows 62 medicines in development in New Jersey, 57 in California, 43 in New York and 41 in North Carolina. (more…)

(Raleigh, N.C.) BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference at the Southampton Inn in Southampton, New York. The presentation is scheduled for Friday, August 13 at 10:00 AM Eastern Time. (more…)

(Research Triangle Park, N.C.) Catalent Pharma Solutions is pleased to announce that the Optiform™ compound optimization platform, a novel, solid-state and highly-automated analysis platform for salt, crystal-form, and co-crystal screening, developed and refined over the past ten years within GlaxoSmithKline (GSK) will now be broadly available to early development scientists for the first time.  The technology has resulted in faster and more material-efficient development workflows, making it easier to bring new drugs to market faster. The Optiform™ compound optimization platform has been applied to more than 500 compounds, spanning from early stage lead compounds through launched products.  GSK has entered into an agreement with Catalent to utilize the Optiform™ platform to support its internal screening activities. The deal between Catalent and GSK was brokered by SR One, GSK’s corporate venture fund. (more…)

(Chapel Hill, N.C.) POZEN Inc. (NASDAQ:POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the second quarter ended June 30, 2010. (more…)

(Washington, D.C.) Pharmaceutical research and biotechnology companies with headquarters or facilities in North Carolina are researching and developing 416 medicines to treat diabetes and closely related conditions, HIV/AIDS and medical disorders that affect women and children.  (more…)

  (Raleigh, N.C.) Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at the BMO Capital Markets 10th Annual Focus on Healthcare Conference in New York, NY on Thursday, August 5 at 1:15 p.m. ET. (more…)

(Burlington, N.C.) Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced results for the quarter ended June 30, 2010. Net earnings were $153.7 million, compared to $136.4 million in the second quarter of 2009. Earnings per diluted share (EPS) were $1.46 compared to $1.24 in 2009. Earnings per diluted share, excluding restructuring and other special charges recorded in the second quarter of 2009 (Adjusted EPS) were $1.30. (more…)

(New York, N.Y.) Berkery Noyes, a leading middle market investment bank, has released its 2010 Half Year Pharma and Healthcare Information and Technology M&A Trends Report. This report analyzes merger and acquisition activity in the Healthcare Industry in the first half of 2010 and compares it with activity in the four previous sixth month periods from 2008-2009. (more…)

(Raleigh, N.C.) Ajinomoto AminoScience LLC (AAS) today announced that it has confirmed GRAS (Generally Recognized As Safe) status of its AjiGRAS-Leucine, meeting the safety standards demanded by the US Food and Drug Administration (FDA). As the only formulation of Leucine currently with FDA acknowledged GRAS status, Ajinomoto’s AjiGRAS-Leucine is the first amino acid to be allowed as an ingredient for use in conventional foods like non-milk and milk based meal replacements, sports and isotonic beverages, vitamin enhanced waters, and meal replacement bars, at levels of 0.5 to 3 grams per serving. (more…)